Search hospitals

>

Colorado

>

Durango

Southwest Oncology PC

Claim this profile

Durango, Colorado 81301

Global Leader in Lung Cancer

Global Leader in Breast Cancer

Conducts research for Breast cancer

Conducts research for Cancer

Conducts research for Pancreatic Cancer

169 reported clinical trials

3 medical researchers

Photo of Southwest Oncology PC in DurangoPhoto of Southwest Oncology PC in DurangoPhoto of Southwest Oncology PC in Durango

Summary

Southwest Oncology PC is a medical facility located in Durango, Colorado. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Pancreatic Cancer and other specialties. Southwest Oncology PC is involved with conducting 169 clinical trials across 347 conditions. There are 3 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, and Mehmet S. Copur.

Area of expertise

1

Lung Cancer

Global Leader

Southwest Oncology PC has run 32 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I
2

Breast Cancer

Global Leader

Southwest Oncology PC has run 27 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Southwest Oncology PC

Bladder Cancer

Lung Cancer

Breast Cancer

Prostate Cancer

Ovarian Cancer

Breast cancer

Esophageal cancer

Multiple Myeloma

Bladder Carcinoma

Testicular cancer

Image of trial facility.

Gemcitabine + Docetaxel vs BCG

for Bladder Cancer

This trial is testing whether a combination of two drugs, Gemcitabine and Docetaxel, given directly into the bladder, is effective for patients with high-grade non-muscle invasive bladder cancer who have not been treated with the standard therapy before. The goal is to see if this new treatment can prevent cancer from coming back or spreading. The study will also look at the quality of life, safety, and side effects of the new treatment. Gemcitabine and Docetaxel have shown promise as an alternative treatment, especially in cases where the standard therapy fails or is not tolerated.

Recruiting

2 awards

Phase 3

14 criteria

Image of trial facility.

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Gemcitabine + Cisplatin

for Bladder Cancer

This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Recruiting

1 award

Phase 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Southwest Oncology PC?